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Breaking and sealing one strand of DnA is an inherent feature of chromosome metabolism 
to overcome torsional barriers. Failure to reseal broken DnA strands results in protein-linked 
DnA breaks, causing neurodegeneration in humans. This is typified by defects in tyrosyl DnA 
phosphodiesterase 1 (TDP1), which removes stalled topoisomerase 1 peptides from DnA termini. 
Here we show that TDP1 is a substrate for modification by the small ubiquitin-like modifier 
sumo. We purify sumoylated TDP1 from mammalian cells and identify the sumoylation site 
as lysine 111. While sumoylation exhibits no impact on TDP1 catalytic activity, it promotes 
its accumulation at sites of DnA damage. A TDP1 sumoylation-deficient mutant displays 
a  reduced  rate  of  repair  of  chromosomal  single-strand  breaks  arising  from  transcription-
associated topoisomerase 1 activity or oxidative stress. These data identify a role for sumo 
during single-strand break repair, and suggest a mechanism for protecting the nervous system 
from genotoxic stress. 
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M
utation  of  tyrosyl  DNA  phosphodiesterase  1  (TDP1) 
underlies the demise of postmitotic neurons observed in 
the human genetic neurological disease Spinocerebellar 
Ataxia with Axonal Neuropathy1. In budding yeast, TDP1 operates 
at DNA double-strand breaks (DSBs) primarily created by collision 
of replication forks with topoisomerase 1 (Top1) intermediates in 
proliferating cells2,3. In higher organisms, TDP1 additionally oper-
ates at single-strand breaks (SSBs), independently of DNA replica-
tion4–6. TDP1-deficient mammalian cells and postmitotic neurons 
display reduced rates of repairing SSBs arising from Top1 activity, 
hydrogen  peroxide  or  ionizing  radiation  (IR)1,4,5,7,8.  TDP1  also 
processes a variety of damaged 3′-termini such as 3′-phosphogly-
colate and 3′-abasic sites7,9–15. Although defects in TDP1 lead to 
accumulation of SSBs, cell-free studies suggest a requirement of 
high  local  concentrations  of  TDP1  to  repair  these  structures16. 
However, it is not clear how this regulation is achieved in cells. Post-
translational  modifications  have  been  implicated  in  modulating 
the function of several DNA repair factors and channel repair to 
specific pathways. For example, phosphorylation of TDP1 by ATM 
or DNA-PK has been shown to promote its function at DSBs17,18. 
Phosphorylation by ATM during DSB repair has also been shown to 
promote the activity of polynucleotide kinase phosphatase19.
Here we identify TDP1 as a target for modification by the small 
ubiquitin-like modifier SUMO and provide evidence implicating 
SUMOylation  in  facilitating  TDP1  cellular  function  during  SSB 
repair.
Results
TDP1 is a substrate for modification by SUMO. Yeast two-hybrid 
analyses  conducted  to  identify  novel  TDP1  binding  partners 
uncovered 14 independent clones encoding full-length UBE2I, the 
human homologue of the yeast SUMO-conjugating enzyme UBC9 
(Fig. 1a). These observations suggested a previously unanticipated 
role for the SUMO modification pathway during TDP1-mediated 
repair. To test whether TDP1 is a substrate for covalent SUMO 
conjugation, we first reconstituted SUMOylation reactions in vitro 
using recombinant human p53, a known SUMO target20 (Fig. 1b).   
Parallel  reactions  conducted  with  human  recombinant  TDP1 
revealed  a  slower  migrating  band,  as  detected  by  anti-TDP1  or 
anti-SUMO1 antibodies (Fig. 1c). These products were absent from 
control reactions conducted in the presence of a SUMO1 mutant 
that  is  incapable  of  forming  the  covalent  conjugation  reaction. 
Furthermore, their appearance was dependent on ATP (Fig. 1d), 
confirming  that  they  are  covalent  TDP1–SUMO1  conjugates. 
Subsequent comparison of the different SUMO isoforms suggested 
that TDP1 is preferentially modified by SUMO1 (Fig. 1e). As most 
SUMO target proteins are modified at very low steady-state levels 
in vivo, we ectopically expressed TDP1 and SUMO1 in mammalian 
cells  and  examined  the  possibility  of  covalent  TDP1–SUMO1 
conjugations. For these experiments, we transfected HEK293 cells 
with Myc–TDP1 and/or green fluorescent protein (GFP)–SUMO1, 
followed  by  immunoprecipitation  using  anti-Myc  antibodies. 
Probing  the  immunoprecipitate  (IP)  with  anti-Myc  antibodies 
revealed a discrete slower migrating band in Myc–IPs from extracts 
coexpressing Myc–TDP1 and GFP–SUMO1 (Fig. 1f). Importantly, 
this band was absent in Myc–IPs conducted on extracts expressing 
either Myc–TDP1 or GFP–SUMO1 alone. Furthermore, probing with 
anti-SUMO1 antibodies revealed a faint band in the input of extracts 
coexpressing  Myc–TDP1  and  GFP–SUMO1,  but  not  in  extracts 
expressing either Myc–TDP1 or GFP–SUMO1 alone. Enrichment 
of this band was observed following Myc–IPs, confirming that it is a 
TDP1–SUMO1 modification. Parallel experiments conducted using 
SUMO1, SUMO2 or SUMO3 isoforms were in agreement with the 
in vitro observations, suggesting that while TDP1 can be modified 
by all three SUMO isoforms its primary substrate appears to be 
SUMO1 (Fig. 1g).
Next, we tested whether endogenous TDP1 is covalently conju-
gated by SUMO1. For these experiments, we used HeLa cells stably 
expressing hexahistidine (6×His)-tagged SUMO1. We purified histi-
dine-tagged SUMO conjugates using nickel-charged beads and sub-
jected the conjugation products to immunoblotting using anti-TDP1 
antibodies. Endogenous TDP1–SUMO1 was enriched on nickel beads 
incubated with extracts expressing histidine-tagged SUMO1, but not 
with control HeLa cell extracts (Fig. 1h). That the enriched products 
correspond to TDP1–SUMO1 conjugates was confirmed by demon-
strating TDP1 activity that releases tyrosine from a 3′-phosphotyrosine   
synthetic Top1 substrate, which mimics Top1-linked DNA breaks 
(Fig. 1i). To further confirm that TDP1 is covalently SUMOylated in 
mammalian cells, we examined the effect of sentrin/SUMO-specific 
protease-1 (SENP1) on human purified SUMO1–TDP1 conjugates. 
SUMOylation is a dynamic process and once attached the SUMO 
peptide can be removed from target proteins by SENPs. For these 
experiments, we transfected HEK293 cells with His–GFP–SUMO1 
and/or  Myc–TDP1  and  purified  histidine-tagged  GFP–SUMO1 
conjugate using nickel-charged beads. Conjugation products were 
then subjected to Myc–IPs to purify Myc–TDP1–SUMO1–His–GFP 
products  (Fig.  1j).  Anti-Myc  immunoblotting  revealed  a  discrete 
band in Myc–IPs from extracts coexpressing Myc–TDP1 and His–
GFP–SUMO1 (Fig. 1k). Subsequent treatment of the Myc–IP with   
SENP1  resulted  in  a  band  corresponding  in  size  to  Myc–TDP1   
(Fig. 1l). Taken together, we conclude that TDP1 is covalently modi-
fied by SUMO1 in mammalian cells.
TDP1 is SUMOylated at lysine 111. To study the consequences of 
TDP1 SUMOylation, we aimed at identifying SUMOylation site(s). 
Most SUMO target proteins contain a specific stretch of ψKxE, 
where ψ is a large hydrophobic residue and K is the target lysine.   
In silico analyses revealed two potential SUMOylation sites in the   
N-terminal domain and three sites in the C-terminal domain (Fig. 2a).   
We mutated the predicted acceptor lysines to arginine and subjected 
the purified proteins to in vitro SUMOylation reactions. Notably, 
the  N-terminal  domain  is  only  conserved  in  higher  eukaryotes   
(Fig. 2b, dotted boxes) and database analyses revealed K111 to be con-
served across vertebrates. Consistent with SUMOylation occurring 
in this domain, reactions conducted in the presence of TDP11 − 150 
revealed a prominent slower migrating band (Fig. 2c, lane 1). This 
band  was  absent  from  reactions  containing  TDP11 − 150;  K111R  
and instead a faster migrating band appeared with lower inten-
sity, suggesting a secondary SUMOylation site that was picked up 
in the absence of K111 in vitro (Fig. 2c, lane 2). Mutation of K139 
to arginine resulted in SUMOylated species with identical size to 
SUMOylated  TDP11 − 150,  albeit  with  higher  intensity,  suggest-
ing that K111 is the main SUMOylation site and that K139 may   
contribute to SUMOylation of the truncated TDP11 − 150 in vitro 
(Fig. 2c, lane 3). Indeed, mutation of both K111 and K139 to arginine 
completely abrogated SUMOylation of TDP11 − 150 (Fig. 2c, lane 4). 
The slower migrating band was SUMOylated TDP1, as it was absent 
in reactions containing a mutant form of SUMO that cannot be   
covalently conjugated (Fig. 2c, lanes 5 and 6). We next compared 
full-length  recombinant  TDP1  and  TDP1K111R  for  their  ability   
to covalently conjugate SUMO1 in vitro. Mutation of lysine 111 to   
arginine  was  sufficient  to  abolish  SUMO1  covalent  attachment 
to full-length TDP1 (Fig. 2d). We next examined whether lysine 
111 is the main SUMOylation site in vivo. For these experiments,   
we generated Myc–TDP1 and mutants in which the N-terminal, 
C-terminal or all predicted SUMO sites were mutated to arginine 
(Fig. 2e). We co-transfected HEK293 cells with the different forms 
of Myc–TDP1 and/or GFP–SUMO1, followed by immunoprecipita-
tion using anti-Myc antibodies. A single amino-acid substitution of 
K111 to arginine was sufficient to abrogate the formation of TDP1–
SUMO1 conjugates (Fig. 2e). Taken together, we conclude that K111 
is the main SUMOylation site in TDP1.ARTICLE     
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SUMOylation-deficient mutant shows reduced rate of SSB repair. 
To  examine  the  consequences  of  TDP1  SUMOylation  in  vivo, 
we  compared  the  ability  of  HEK293  cells  ectopically  expressing 
SUMO1 and TDP1 or TDP1K111R for their ability to repair camp-
tothecin (CPT)-induced DNA damage using alkaline comet assays. 
These assays primarily measure repair of DNA SSBs, where they 
form and disappear with kinetics established for this repair proc-
ess4,5,21. As expected, HEK293 cells expressing TDP1 accumulated 
four- to fivefold fewer SSBs compared with control cells (Fig. 3a). 
Notably, cells expressing TDP1K111R accumulated two- to three-
fold more SSBs compared with TDP1-expressing cells (P = 0.0169;   
t-test). This defect was not due to differences in expression levels as 
confirmed by immunoblotting (Fig. 3b) and was evident from scat-
ter plots of the raw data from individual experiments (Fig. 3c). The 
difference in breaks is notable in terms of SSB repair, as ~4-fold dif-
ference underlies the severe neurological demise observed in neural 
tissues lacking XRCC1, the core SSB repair protein22. To examine 
whether the difference in repair was due to SUMOylation, we com-
pared CPT-induced SSBs in the presence and absence of ectopically 
expressed SUMO1. While overexpression of SUMO1 had no impact 
on CPT-induced SSBs in control cells and in TDP1K111R-expressing   
cells (Fig. 3d,e; P = 0.65; t-test), it reduced the extent of SSBs in 
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Figure 1 | Human TDP1 is SUMOylated in vitro and in mammalian cells. (a) Yeast Y190 cells containing the indicated constructs were examined for  
the activation of His3 and β-Gal reporter genes. (b) Recombinant p53 (430 nm) was incubated with 50 nm sAE1/sAE2, 500 nm uBC9, 5 mm ATP  
and 30 µm sumo1 ‘WT’ or mutant sumo1 that cannot be covalently conjugated ‘mT’. Reactions were fractionated by sDs–PAGE and analysed  
by anti-p53 immunoblotting (Activemotif). (c) Human full-length TDP1 (500 nm) was subjected to in vitro sumoylation reactions and analysed  
by anti-TDP1 (ab4166; Abcam) or anti-sumo1 (santa Cruz, sC-5308) immunoblotting. (d) sumoylation reactions were conducted in the presence 
or absence of 5 mm ATP. (e) sumoylation reactions conducted in the presence of sumo1, sumo2 or sumo3 were divided into three fractions and 
analysed by immunoblotting. (f) Total cell extract from HEK293 (~4×106 cells) transfected with myc–TDP1 and/or GFP–sumo1 was subjected to 
immunoprecipitation using anti-myc monoclonal antibodies (9B11; Cell signaling). Immunoprecipitates were analysed by immunoblotting using anti-myc 
(9B11) or anti-sumo1 (sC-5308) antibodies. Input is ~5% of total cell extract. (g) HEK293 cells transfected with myc–TDP1, HA-tagged His–sumo1,  
His–sumo2 or His–sumo3 were analysed by anti-TDP1 (ab4166) or anti-His (H1029) immunoblotting. (h) Lysates from control HeLa cells ‘C’ or cells 
stably expressing His–sumo1 ‘s1’ were mixed with ni2 +  charged agarose beads and histidine-tagged sumo conjugates ‘bound’ were analysed by  
anti-TDP1 immunoblotting. Input is ~3% of total cell extract. (i) Total cell extract ‘In’ (~20 µg) or ni2 +  beads enriched with histidine-tagged sumo 
conjugates ‘bound’ were mixed with 32P-radiolabelled 18-mer duplex (50 nm) harbouring a 3′-phosphotyrosine terminus ‘PY’, inset. Repair products were 
analysed by denaturing PAGE and phosphorimaging. Positions of the 32P-radiolabelled substrate ‘PY’ and product ‘P’ are indicated. (j) Diagram depicting 
purification of sumoylated TDP1 from mammalian cells. (k) serial dilutions of purified myc–TDP1 or myc–TDP1–sumo1–His–GFP were analysed by 
sDs–PAGE and anti-myc immunoblotting. (l) Purified myc-TDP1–sumo1–His–GFP was mock-treated ‘ − ’ or incubated with 250 ng of human sentrin/
sumo-specific protease-1 (sEnP1) ‘ + ’ and reaction products analysed by anti-myc immunoblotting. molecular weight size markers (kDa) are depicted. 
IB, immunoblot; IgG, immunoglobulin G; mT, mutant; WT, wild type.ARTICLE
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TDP1-expressing cells (P = 0.007; t-test). These observations suggest 
that the difference in repair observed between TDP1K111R and TDP1 
was due to SUMOylation of the latter. As TDP1 also repairs oxida-
tive SSBs resulting from IR23, we compared TDP1- and TDP1K111R-
expressing cells for their ability to repair IR-induced SSBs. While 
IR induced similar levels of SSBs in all three cell lines (Fig. 3f), the 
kinetics of their removal was delayed in cells expressing TDP1K111R 
compared with TDP1-expressing cells (Fig. 3g), suggesting a role for 
TDP1 lysine 111 during the repair of IR-induced SSBs.
To further examine the consequences of TDP1 SUMOylation in 
cells lacking endogenous TDP1, we infected Tdp1 − / −  mouse embry-
onic fibroblasts (MEFs) with retrovirus particles containing vector 
alone  (Tdp1 − / −   V)  or  encoding  human  TDP1  (Tdp1 − / −   hTDP1)   
or TDP1K111R (Tdp1 − / −  hTDP1 − K111R). During 30-min incubation 
with CPT, Tdp1 − / −  V accumulated approximately fivefold more SSBs 
compared with cells complemented with wild-type human TDP1, 
Tdp1 − / −  hTDP1 (Fig. 3h). Importantly, Tdp1 − / −  hTDP1 − K111R cells 
accumulated ~3-fold more breaks compared with Tdp1 − / −  hTDP1  
cells (P = 0.015; t-test). Consistent with the kinetics of SSB repair, 
subsequent  incubation  in  CPT-free  medium  for  short  periods 
resulted  in  a  decline  in  the  level  of  SSBs  observed  in  all  three 
cell  lines.  Notably,  levels  of  SSBs  remained  at  a  higher  level  in   
Tdp1 − / −  hTDP1 − K111R compared with Tdp1 − / −  hTDP1 cells. To exam-
ine whether unrepaired SSBs in Tdp1 − / −  hTDP1 − K111R impacted on 
cellular survival, we compared the three cell types for their ability to 
form macroscopic colonies following exposure to CPT. Tdp1 − / −  V  
cells  were  very  sensitive  to  CPT  and,  as  expected,  complemen-
tation  with  hTDP1  led  to  marked  protection,  whereas  comple-
mentation  with  hTDP1K111R  led  to  partial  protection  (Fig.  3i,j).   
Furthermore,  complementation  of  Tdp1 − / −   quiescent  cortical   
neural cells with human TDP1 or TDP1K111R revealed a role for 
K111  to  maintain  cell  viability  following  CPT  (Fig.  3k).  Taken 
together, we conclude that mutating the acceptor lysine K111 to a 
non-SUMOylatable arginine results in defects in repairing SSBs.
K111R does not alter TDP1 structure or catalytic activity. Why 
does  a  TDP1  SUMOylation-defective  mutant  display  attenuated 
rates of SSB repair? Although unlikely for missense point muta-
tions,  we  tested  the  possibility  that  the  K111R  mutation  might 
lead to a gross distortion of TDP1 structure. We subjected recom-
binant  TDP1  and  TDP1K111R  produced  in  Escherichia  coli  to   
thermal  denaturation  experiments,  a  widely  used  technique  to 
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examine structural changes of proteins24. The K111R mutation had 
no detectable impact on the thermal stability or unfolding profile 
of  TDP1,  as  determined  by  comparing  the  denaturation  curves 
and their corresponding melting temperatures (Fig. 4a). We also 
compared  the  circular  dichroism  absorption  spectrum  of  TDP1 
and TDP1K111R (Fig. 4b–d). The two proteins gave spectral shapes 
with negative bands at ~210 and 220 nm, and positive bands at 
~195 nm. Analyses of secondary structure by the variable selection 
algorithm (CDSSTR), which provides superior fits for globular pro-
teins25–28, revealed no significant difference in α-helical or β-sheet 
content (P > 0.5; t-test), suggesting no apparent change in structure   
(Supplementary Table S1). This was also supported by using the 
CONTIN and K2D algorithms (Supplementary Tables S2 and S3).   
To further examine the impact on protein folding and catalytic activity, 
we incubated purified recombinant TDP1 or TDP1K111R with oli-
gonucleotide duplexes harbouring 3′-phosphotyrosine that mimic   
Top1-linked breaks and quantified the 3′-phosphate products. The 
reactions showed a comparable concentration-dependent conver-
sion of 3′-phosphotyrosine to 3′-phosphate, suggesting no impact of 
the K111R mutation on catalytic activity (Fig. 4e,f). Taken together, 
we conclude that mutation of the SUMOylation site of TDP1 to a 
non-SUMOylatable version results in delayed rate of SSB repair 
without a measurable impact on structure or catalytic activity.
SUMOylation of  TDP1 does not alter enzymatic activity. Next, 
we considered the possibility that SUMOylation may alter protein 
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function by introducing structural changes that result in changes 
in  enzymatic  activity29,30.  To  test  this  possibility,  we  subjected 
human recombinant TDP1 or TDP1K111R to SUMOylation reac-
tions in the presence of wild-type SUMO1 or mutant SUMO1 (Fig. 
4g) and incubated reaction products with the synthetic Top1 sub-
strates (Fig. 4h–j). We also compared the effect of SUMOylation on 
TDP1 produced in mammalian cells (Fig. 5a,c,e,f). Furthermore, we 
subjected purified human SUMOylated TDP1 to SENP1 treatment 
and compared the activity of the resulting products to that of mock-
treated  fractions  (Fig.  5b,d,g,h).  Incubation  of  Myc–TDP1  with 
Top1-substrate mimics resulted in a dose-dependent conversion of 
3′-phosphotyrosine to 3′-phosphate, indicating that TDP1 catalytic 
activity was not affected by Myc, His or GFP tags. Quantification   
of reaction products at different concentrations or at different time 
points revealed no marked impact of SUMOylation on TDP1 activ-
ity (Fig. 5e–h). We conclude from these experiments that SUMO1 
conjugation to TDP1 does not affect its enzymatic activity. We also 
excluded  the  possibility  that  TDP1  SUMOylation  might  modu-
late interaction with DNA ligase IIIα (Lig3α), a known binding 
partner and a component of the SSB repair machinery (Fig. 6a,b). 
Using western blotting, we could not detect a measurable increase 
of TDP1 SUMOylation after exposure to exogenous DNA damage 
(Supplementary Fig. S1). This suggests that TDP1 SUMOylation is a 
housekeeping modification that occurs, as is also the case with other 
SUMO1-modified targets such as fission yeast Top1 and human 
Kap1 (refs 31 and 32), at low steady-state levels where cycles of   
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conjugation and deconjugation are associated with endogenous lev-
els of DNA breaks. Furthermore, SUMOylation did not alter TDP1 
nucleolar exclusion after DNA damage, as determined by live and 
fixed cell fluorescence microscopy (Fig. 6c–e).
SUMOylation aids accumulation of TDP1 at sites of DNA damage.   
We  next  considered  the  possibility  that  TDP1  SUMOylation 
might affect its local concentration at sites of DNA damage. This 
would be an appealing mechanism to increase substrate spectrum,   
as in vitro data suggest a requirement for a high concentration of 
TDP1 to process SSBs16,23. The difference in unrepaired SSBs that 
accumulate in TDP1K111R compared with TDP1-expressing cells 
could  be  attributed  to  differences  in  the  local  concentration  of 
TDP1 at sites of DNA damage (Supplementary Fig. S2). To exam-
ine whether TDP1 SUMOylation fulfils this function, we compared 
the accumulation of GFP–TDP1 to that of GFP–TDP1K111R at sites 
of ultraviolet A laser-induced DNA damage in mammalian cells. 
Laser damage induces a mixture of nicks, gaps, SSBs and DSBs, all 
of which have been shown to trap Top1, resulting in Top1–DNA 
breaks33–35. In addition, a subset of these breaks may be direct sub-
strates for TDP1 (refs 7,12 and 36). While GFP–TDP1 accumulated 
rapidly at sites of laser damage reaching a maximum level within 
5 s, accumulation of GFP–TDP1K111R was slower and less exten-
sive  (Fig.  7a–c).  Interestingly,  accumulation  of  GFP–TDP1K111R 
continued to increase over the entire time course of the experi-
ment, perhaps reflecting the need to continue protein accumula-
tion to achieve levels similar to that seen with GFP–TDP1. 90 s after 
DNA damage, the local enrichment of GFP–TDP1 at laser stripes 
was ~150% compared with ~125% for GFP–TDP1K111R (Fig. 7a). 
This  difference  was  not  due  to  differences  in  TDP1  expression,   
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as the global expression was similar by western blotting (Fig. 7a, 
inset) and, more importantly, only cells that showed similar level 
of  GFP–TDP1  total  fluorescence  were  subjected  to  the  tracking 
experiments (Fig. 7b). Notably, the K111R mutation did not ablate 
recruitment completely, suggesting that either recruitment is par-
tially SUMOylation-dependent or other SUMO sites, although not 
detected biochemically, may contribute to the remaining fraction of 
enrichment.
If it is true that TDP1 SUMOylation promotes repair by facili-
tating its accumulation at sites of DNA damage, then depletion of 
UBE2I (UBC9), the obligate SUMO-conjugating enzyme, should 
similarly reduce accumulation of TDP1 at sites of DNA damage.   
To test this, we depleted UBC9 in MRC5 cells using short hair-
pin  RNA  and  compared  the  accumulation  of  GFP–TDP1.  As 
predicted, depletion of UBC9 led to a marked reduction of the 
ability  of  GFP–TDP1  to  accumulate  at  sites  of  laser  damage 
(Fig.  7b–f).  Enrichment  of  GFP–TDP1  in  UBC9-depleted  cells   
displayed similar dynamics to that of GFP–TDP1K111R, as it contin-
ued to increase during the time course of the experiment. Impor-
tantly, depletion of UBC9 did not result in further reduction in the   
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accumulation  of  GFP–TDP1K111R,  indicating  that  the  observed 
effect  was  due  to  SUMOylation.  Taken  together,  these  results   
indicate that SUMOylation of TDP1 at K111 facilitates its accumu-
lation at sites of DNA damage, thereby enhancing its DNA repair 
capacity.
Contribution  to  the  repair  of  transcription-associated  SSBs.   
A major source of Top1-breaks is the collision of Top1 intermediates   
with  elongating  RNA  polymerases  during  transcription.  Inhib-
iting  RNA  polymerase  II  by  5,6-dichlorobenzimidazole  1-b-d- 
ribofuranoside (DRB) or α-amanitin has been shown to reduce the 
extent of CPT-induced DNA SSBs4,37. We reasoned that if TDP1 
SUMOylation contributes to its recruitment to sites of transcription- 
associated  SSBs,  then  inhibiting  transcription  should  result  in 
reduced accumulation of TDP1. Consistent with this prediction, 
pretreatment of GFP–TDP1-expressing cells with the transcription 
inhibitor DRB led to reduction in TDP1 accumulation at sites of 
laser damage (Fig. 8a,b). The reduction in recruitment was less than 
that observed for mock-treated GFP–TDPK111R, which could reflect 
a role for TDP1 SUMOylation during damage generated by DRB-
resistant RNA polymerases. Alternatively, it could be due to roles 
for  TDP1  SUMOylation  unrelated  to  transcription.  Importantly, 
DRB  did  not  affect  the  initial  recruitment  of  GFP–TDP1K111R,   
suggesting a role for TDP1 SUMOylation at K111 during the repair 
of transcription-blocking lesions. However, DRB ablated the time-
dependent increase of GFP–TDP1K111R accumulation during the 
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subsequent  90-s  observation  period.  We  reason  that  inhibiting 
transcription may reduce the frequency of collision of Top1 inter-
mediates with elongating RNA polymerase II, thereby reducing the 
need for recruiting more GFP–TDP1K111R. We next quantified the 
extent of transcription-associated SSBs using alkaline comet assays. 
For  these  experiments,  we  used  HEK293  cells  to  achieve  ~90% 
transfection efficiency. If the difference in repair capacity observed 
between TDP1 and TDP1K111R was, at least in part, due to a role 
for TDP1 SUMOylation in repairing transcription-associated SSBs, 
then inhibiting transcription should ablate or reduce this difference. 
While cells expressing TDP1K111R accumulated a higher level of 
SSBs compared with TDP1 expressing cells, they both decreased to a 
comparable level following incubation with DRB (Fig. 8c,d; P = 0.78; 
t-test), suggesting that TDP1 SUMOylation contributes to the repair 
of transcription-associated SSBs. Taken together, these data suggest 
that TDP1 SUMOylation at K111 participates in the overall repair 
of transcription-dependent SSBs.
Discussion
Top1-linked DNA breaks underlie the clinical utility of an important 
class of anticancer drugs, and their progressive accumulation causes 
neurodegeneration in humans1,38–40. A key factor in the repair of 
Top1-breaks is TDP1, mutation of which causes the demise of post-
mitotic tissue. Here we report that TDP1 is a substrate for SUMO 
modification, which occurs primarily at lysine 111 within the vertebrate- 
conserved N-terminal domain. SUMOylation promotes accumula-
tion of TDP1 at sites of DNA damage, thereby accelerating the rate of 
SSB repair and contributes, at least in part, to the repair of transcrip-
tion-generated SSBs, the major source of Top1-breaks in non-cycling 
cells. These observations raise the possibility of an important regula-
tory role in postmitotic tissue. Notably, ~4-fold difference in the rapid 
clearance of SSBs results in severe neurological dysfunction in murine 
model systems22 and has been linked to ataxia in humans1,41,42.
Collision  of  elongating  RNA  polymerase  II  with  Top1  inter-
mediates  results  in  stalling  of  transcription  and  triggers  partial 
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Figure 8 | Accumulation of TDP1 at sites of DNA damage is in part transcription dependent. (a) mRC5 cells expressing GFP–TDP1 or GFP–TDP1 K111R 
were incubated with Dmso ‘-DRB’ or with 50 µm 5,6-dichlorobenzimidazole 1-b-d-ribofuranoside ‘ + DRB’ for 2 h at 37 °C. Cells expressing similar  
total GFP signal were irradiated with an ultraviolet A laser, and GFP–TDP1 accumulation at the site of damage was quantified. Data are the mean ± s.e.m.  
of ~40 cells from n = 4 biological replicates. note that the difference between the accumulation of GFP–TDP1 in the absence (yellow circles) and  
presence (yellow triangles) of DRB was statistically significant (P < 0.05, student’s t-test). (b) Average total fluorescence ± s.e.m. for cells analysed in a. 
(c) HEK293 cells were transfected with empty vector ‘vector’, myc–TDP1 ‘TDP1’ or myc–TDP1K111R ‘TDP1 K111R’ and GFP–sumo1. Cells were incubated 
with Dmso ‘mock’ or treated with 50 µm camptothecin ‘CPT’ with or without previous incubation with 50 µm DRB for 2 h. DnA strand breakage was 
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(a tiny proportion), and the balance is maintained by the opposing activities of sumo conjugation (sAE1/2, uBC9 and possibly a sumo ligase) and 
deconjugation (sEnPs). We show that TDP1 sumoylation occurs primarily at K111 and propose that sumoylated TDP1 is at least, in part, engaged  
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degradation of Top1 to a small peptide43. TDP1 can then access 
these structures to remove the stalled Top1 peptide from DNA ter-
mini23,44. We propose that collision with RNA polymerases is a trig-
ger to degrade Top1 and to subsequently enrich TDP1 at sites of 
DNA damage (Fig. 8e). The latter process is, at least in part, depend-
ent on SUMOylation of TDP1 at lysine 111. We propose a further, 
evolutionarily  conserved,  layer  of  regulation  via  a  SUMO–SIM 
interaction that maintains TDP1 at sites of DNA damage. There is 
precedence for the involvement of SUMO during Top1 repair. Top1 
itself, the main source of DNA breaks that require TDP1, is also a 
substrate for SUMO conjugation45,46. In fission yeast, the SUMO 
conjugation  machinery  also  has  a  role  for  dealing  with  Top1-
breaks47. The Nse2 E3 SUMO ligase functions together with the 
fission yeast structure-specific nuclease Rad16-Swi10 to facilitate 
the repair of Top1-breaks, independently of Tdp1 (refs 32 and 48). 
Notably, lysine 111 is absent in fission yeast Tdp1, highlighting an 
evolutionarily driven SUMO regulation for human TDP1.
Mutation of the SUMO acceptor lysine 111 to arginine did not 
result in an apparent impact on the core structure of TDP1, as indi-
cated by the thermal shift profiles, circular dichroism spectrograms 
and by comparing enzymatic activities of the recombinant proteins. 
While CD spectra showed no significant change in α-helical or   
β-sheet content, it pointed at a possible minor change in conforma-
tion, which is unlikely to be of biological relevance, as enzymatic 
activities was not affected. Moreover, cellular TDP1 and TDP1K111R 
interacted to the same extent with Lig3α, which is known to bind to 
that domain17,18, as measured by two independent assay methods 
(Fig. 6). Knockdown of UBC9 reduced recruitment of TDP1 to a 
level similar to that of TDP1K111R, but had no impact on TDP1K111R 
recruitment, indicating that the difference was due to SUMOyla-
tion. Furthermore, overexpression of SUMO1 facilitated repair of 
cells expressing TDP1, but not TDP1K111R, further supporting that 
the observed phenotype was due to SUMOylation.
Crystal  structure,  cell-free  and  DNA  binding  studies  suggest 
that  high  local  concentrations  of  TDP1  are  required  to  process 
Top1–SSBs16,49,50. However, how vertebrate cells achieve this was 
not clear5,16,51. Here we examined whether SUMOylation of TDP1 
increased its catalytic activity, using the 3′-phosphotyrosine sub-
strate to mimic Top1-linked DNA breaks. SUMOylated TDP1 pre-
pared in vitro or purified from mammalian cells exhibited similar 
catalytic activity to the unSUMOylated version. It is possible that 
SUMOylation facilitates binding of Top1 peptide to the peptide-
binding pocket of TDP1 and thus increases catalytic activity when 
using a peptide substrate instead of a phosphotyrosine substrate. 
However, we do not favour this possibility, as the peptide-binding 
pocket is distant form the SUMOylation site. Instead, our results 
show that SUMOylation promotes TDP1 accumulation at sites of 
DNA damage, ensuring sufficiently rapid and proficient repair of 
SSBs (Figs 7 and 8). SUMOylation has been previously implicated 
in  concentrating  enzymatic  activities  and  triggering  the  forma-
tion of nuclear assemblies, such as PML bodies52,53; however, it 
has not been linked to repair of SSBs, a highly abundant form of 
endogenous DNA damage and a major threat to genome integrity. 
Notably, we observed that persistent overexpression of TDP1, but 
not  the  SUMOylation-defective  mutant,  was  poorly  tolerated  in 
mammalian cells. This is likely due to the efficient accumulation 
of TDP1 at damaged sites with subsequent generation of excessive 
3′-phosphate termini that require further processing by limiting 
downstream factors such as PNK54. Thus, SUMOylation appears 
to target specifically a subset of TDP1 to promote sufficiently rapid 
turnover of endogenous Top1–SSBs. It is not known at what level 
Top1-breaks arise in cells. However, the fact that they do arise in   
the absence of exogenous DNA damage is suggested by the pro-
gressive degeneration of the cerebellum of patients with defective   
TDP1  and  by  experiments  in  fission  yeast  where  depletion  of   
Tdp1 and parallel pathways led to the generation of Top1-breaks1,32. 
Thus,  devising  efficient  mechanisms  to  deal  with  endogenous   
Top1-breaks  is  critical  for  the  maintenance  of  genetic  integrity,   
particularly in postmitotic tissue.
In summary, we report here that human TDP1 is SUMOylated at 
lysine 111 and that SUMOylation promotes its accumulation at sites 
of damaged DNA, thereby facilitating the repair of SSBs. These data 
identify a molecular role for SUMOylation during TDP1-mediated 
SSB repair reactions and implicates this process in protecting post-
mitotic tissue from genotoxic stress.
Methods
Yeast two-hybrid screen and analyses. Sacharomyces cerevisiae Y190 cells 
(Clontech) were transformed with pGBKT7–TDP1S81E, and transformants were 
plated onto minimal media plates (glucose and yeast nitrogen base without amino 
acids) additionally containing adenine, histidine and leucine. Pooled populations 
of transformants were streaked and single clones picked to ensure good expression 
of the fusion proteins. Y190 cells expressing pGBKT–TDP1S81E were transformed 
with 16 µg of pACT human cDNA library and transformants plated onto minimal 
media supplemented with adenine and 50 mM 3-amino-1,2,4-triazole (3AT), but 
lacking leucine, tryptophan and histidine (His-). The activation of the His reporter 
gene was indicated by growth on His- plates after 4–7 days at 30 °C. A total number 
of 5×106 clones were screened, as estimated from the transformation efficiency on 
minimal media plates with adenine and histidine. Healthy-looking colonies were 
isolated, rescreened for growth on His- plates. Potential clones were tested for  
the activation of the β-Gal reporter by qualitative X-Gal (5-bromo-4-chloro- 
3-indolyl-β-d-galacto-pyranoside) assays on colony filter lifts from control plates. 
Following confirmation of positive clones, the corresponding pACT constructs 
were isolated and subjected to sequencing. We identified 14 independent clones 
encoding full-length human UBE2I according to the published DNA sequence 
(NM_003345). Antibodies used for the detection of fusion proteins are listed in 
Supplementary Methods.
Cell-free SUMOylation assays. The generation and purification of recombinant 
proteins and their quantification are detailed in Supplementary Methods. Puri-
fied His–TDP1 or His–TDP1 mutants (430 nM) were incubated with purified 
SAE1/SAE2 (50 nM), UBC9 (500 nM), SUMO1, SUMO2 or SUMO3 (30 µM) in 
50 mM Tris–HCl, pH 8.0; 50 mM NaCl, 5 mM MgCl2, 10% glycerol, 0.5 mM DTT 
and 5 mM ATP (Activemotif). Reactions were incubated at 30 °C for 3 h unless 
otherwise indicated, followed by fractionation on SDS–PAGE and analyses by west-
ern blotting using anti-SUMO1, anti-SUMO2/3, anti-p53 (Activemotif, 1:3,000) or 
anti-TDP1 polyclonal antibodies (ab4166; Abcam, 1:2,000). Note that we noticed 
a nonspecific binding of the anti-SUMO1 antibodies (Activemotif) to unmodified 
SUMO1 targets. To confirm that the modification is in fact for SUMO1, we also 
used anti-SUMO1 monoclonal antibodies from Santa Cruz (clone 0–11; SC-5308, 
1:2,000). While both antibodies recognized the same SUMOylated species, the  
latter did not pick up the unmodified protein.
Circular dichroism spectroscopy. Recombinant proteins were dialysed in 30 mM 
sodium phosphate buffer, pH 7.4, and filtered immediately before the spectrum  
was obtained through 0.2-micron filters (Millipore). The concentration of  
recombinant proteins was accurately determined immediately before, during  
and after the CD scans, to ensure accurate secondary structure estimations. 
Samples were normalized to the lowest concentration (0.6 mg ml − 1), placed in 
a 0.2-mm quartz cuvette (Starna, Essex, UK) and measurements taken using a 
JASCO J-715 spectropolarimeter (JASCO). The CD spectrum of the buffer alone 
was subtracted from that of the sample, and time constant was set to 4 s with a  
scan rate at 50 nm min − 1. The bandwidth was 1 nm and the sensitivity set to 
standard. Scans were performed from 260 to 190 nm with a 0.1-nm data pitch and 
continuous scan mode. A Peltier device was used to maintain a temperature at 
10 °C. The buffer baselines were subtracted and data represent the average of four 
independent experiments ± s.e.m.
Immunoprecipitation. The generation and maintenance of mammalian cells are  
provided in Supplementary Methods. HEK293 (~1.5×106) cells were transfected 
using standard calcium phosphate precipitation, and 2 days later, cells were lysed in 
200 µl lysis buffer (20 mM HEPES pH7.4, 0.5% NP40, 40 mM NaCl, 2 mM MgCl2,  
1× protease inhibitor cocktail (Roche) 1× phosphatase inhibitor cocktail (Roche), 
20 mM N-ethyl maleimide, 25 U ml − 1 benzonase (Merck)). Lysates were incubated 
for 30 min on ice, cleared by centrifugation at 13,000 r.p.m. for 10 min, and NaCl 
concentration adjusted to either 150 mM for coimmunoprecipitation to examine 
protein–protein interaction or 300 mM to detect in vivo SUMOylation. Anti-Myc 
antibodies (9B11; Cell Signaling) were added to the lysate at 1 µl per 200 µl lysate 
volume and the mixture was rotated at 4 °C for 1 h. Following centrifugation at 
13,000 r.p.m. for 10 min, supernatant was then added to protein-G sepharose  
beads (Sigma), followed by rolling at 4 °C for 1 h. Beads were washed three times 
with wash buffer (20 mM HEPES, pH 7.4, 150 mM or 300 mM NaCl) and then 
resuspended in SDS loading buffer for analyses by immunoblotting.ARTICLE
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Purification of SUMOylated TDP1 from human cells. Approximately 1×107 
HEK293 cells were transfected with plasmids encoding GFP–His–SUMO1 and 
Myc–TDP1 and lysed, as described above, using 2× protease inhibitors and 30 mM 
imidazole in both the lysis and wash buffer. Following washing, SUMOylated pro-
teins were eluted from the beads using three consecutive elutions with lysis buffer 
containing 250 mM imidazole. Elution fractions were pooled and SUMOylated 
TDP1 was purified using Myc-immunoprecipitation, as described above. Beads 
enriched with SUMOylated TDP1 were finally suspended in an equal volume of 
wash buffer. Where indicated, 80 µl bead suspension enriched with purified Myc–
TDP1–SUMO1 was resuspended in 150 mM NaCl, 50 mM Tris, pH 7.5, 0.5 mM 
DTT. A volume of 40 µl bead suspension was then mock-treated or incubated with 
0.2–1 µg of human sentrin/SUMO-specific protease-1 (SENP1; Enzo Life Sciences) 
for 20 min at 37 °C. Following three consecutive washes with 150 mM NaCl, 50 mM 
Tris, pH 7.5, beads were subjected to in vitro activity assays or analysed by im-
munoblotting with anti-TDP1 or anti-Myc antibodies. Quantification of purified 
Myc–TDP1 and Myc–TDP1–SUMO1–His–GFP was conducted by comparing 
with known concentrations of recombinant His–TDP1 by western blotting. The 
latter was determined by Bradford assays, and by comparing with Coomassie-
stained BSA standards. We estimate 2 ng µl − 1 bead suspension of purified human 
Myc–TDP1 or Myc–TDP1–SUMO1–His–GFP.
Cell-free DNA repair assays. Purified recombinant proteins were subjected  
to in vitro SUMOylation reactions and the appropriate dilutions were mixed with 
50 nM 32P-labelled oligonucleotide duplexes (see Supplementary Methods for  
DNA sequence) in 8 µl total volume in 25 mM HEPES, pH 8.0, 130 mM KCl  
and 1 mM DTT. Purified SUMOylated TDP1 from mammalian cells was  
quantified as described above and serial dilutions of beads were mixed with  
50 nM 32P-labelled substrates. Reactions were incubated for 1 h at 37 °C,  
terminated by formamide loading buffer, fractionated by denaturing PAGE,  
and analysed by phosphorimaging.
Cellular SSB repair assays. HEK293 cells or Tdp1 − / −  MEFs containing empty 
vector or vectors expressing wild-type TDP1, TDP1K111R or GFP–SUMO1 were 
subjected to 20 µM CPT (MEFs) or 50 µM CPT (HEKs) for 30 min at 37 °C, or 
exposed to 20 Gy IR (caesium 137, Cammael 1000) on ice. Where indicated, cells 
were subsequently incubated in drug-free media for the indicated repair periods. 
DNA strand breakage was quantified by alkaline comet assays as described in  
Supplementary Methods.
Clonogenic survival and viability assays. Following confirmation of expression 
by anti-TDP1 western blotting, Tdp1 − / −  MEFs complemented with empty vector 
or with vectors expressing wild-type TDP1 or TDP1K111R were plated in duplicate 
into 10-cm dishes (~2,000 cells; untreated, 6,000 cells; CPT doses 2.5 and 5 µM, 
and ~10,000 cells; CPT doses 7.5 and 10 µM) and incubated at 37 °C for at least 
8 h. Cells were then mock-treated or treated with the indicated doses of CPT for 
1 h at 37 °C. Cells were washed with PBS (3×) and then incubated for 7–10 days in 
drug-free medium to form macroscopic colonies. Colonies were fixed using 90% 
ethanol and stained with 1% methylene blue. Survival was calculated by dividing 
the average number of colonies on treated plates by the average number of colonies 
on untreated plates. Cortical neural cells were grown to confluency at 20% oxygen 
to elevate the oxidative load and then deprived from growth factors for 3 days, 
followed by electroporation with GFP–TDP1 or GFP–TDP1K111R using Neon 
transfection system, according the manufacturer’s instructions (Invitrogen). Cells 
maintained at high oxygen were exposed to fractionated pulses of 30 µM CPT  
(4× 30 min pulse every 3 h), and viability of GFP-positive cells was quantified  
from blindly coded slides using propidium iodide (Sigma) exclusion.
Laser microirradiation. Exponentially growing human MRC5 cells were plated 
onto 35-mm glass-bottom dishes (MatTek) and transfected with pMCEGFP–TDP1 
or pMCEGFP–TDP1K111R using GeneJuice (Novagen), according to the manufac-
turer’s protocol. Twenty-four hours following transfection, cells were incubated 
with 10 µg ml − 1 Hoechst 33285 (Sigma) for 1 h at 37 °C before irradiation. Where 
indicated, cells were additionally incubated with DMSO or 50 µM DRB for 2 h 
before irradiation. Cells expressing similar total GFP signal were irradiated with a 
351-nm ultraviolet A (4.36 J m − 2) laser channelled through a ×40/1.2-W objective 
using a Zeiss ConfoCor 2/LSM510 combi meta point scanning confocal micro-
scope (Zeiss). Ultraviolet A was focused to an area of approximately 12 µm×0.1 µm, 
and images were captured at 5-s intervals following laser damage and quantified  
by ImageJ and LSM 520 Meta software. 
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